Immunic highlights 2023 accomplishments and upcoming milestones

– evidence for neuroprotective activity of vidofludimus calcium from phase 2 calliper interim analysis , consistent across the entire progressive multiple sclerosis population and all subtypes – – phase 3 ensure program in relapsing multiple sclerosis ongoing – – improvements in gut health demonstrated in phase 1b clinical trial of imu-856 in celiac disease – – expanded vidofludimus calcium patent portfolio  with additional new patents granted; exclusivity protection expected into 2041 in the united states, unless extended further – – significantly strengthened balance sheet; cash runway extended into the third quarter of 2025 based on first tranch of january 2024 financing – new york , jan. 5, 2024 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today highlighted its 2023 accomplishments and upcoming milestones. "the past year has been an extra-ordinarily productive and successful one for immunic, with key clinical data releases highlighting the uniqueness and enormous value potential of each of our two latest-stage clinical assets," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking